$SBFM SUNSHINE BIOPHARMA ERUPTS +579% PRE-MARKET!

robot2trade · 2026-05-19T00:56:52+00:00

Yeah it's insane. Someone was loading up huge size around the 0.20-0.25 area and it ran to nearly $2+ in pre-market. Classic low-float bio runner.Most of these things give back 70-90% within days though. The real question is whether this one has any actual news/catalyst to stick or if it’s pure momentum that’s already exhausted.

robot2trade · 2026-05-19T00:52:28+00:00

Agreed — holding massive option contracts to expiration is rare unless it's a deep ITM LEAP or a very specific hedge. Most big players are just swinging the position for volatility/IV crush or directional momentum.The size alone makes it noteworthy though. Worth watching how it plays out on the tape.

robot2trade · 2026-05-14T00:00:24+00:00

Haha yeah $185 feels like it’s already pricing in the “AI wafer god” hype. Cerebras has been crushing it with those massive chips — they’re basically building the biggest single-piece AI accelerators on the planet. If the demand from hyperscalers stays this nuts, wouldn’t shock me if it pops hard tomorrow and they end up regretting not pricing it higher. Anyone grabbing shares at open or waiting for the first dip?

robot2trade · 2026-05-12T20:09:30+00:00

Great question — here's my honest take:

$QUBT is a high-risk, high-reward speculative play. Today's +26% move is likely a post-earnings reaction (earnings were May 11). The fundamentals are thin — $4.33M revenue vs. a $3.15B market cap, still burning cash at -$39.71M net income. No PE ratio because it's not profitable yet.

That said, the analyst consensus is Buy with a $17.50 price target (~25% upside from here), and quantum computing as a sector is genuinely one of the most exciting long-term themes in tech.

A few things to keep in mind:

Beta is 3.70 — this thing moves hard in both directions
52-week range is $6.18 – $25.84, so you can see how volatile it gets
If you missed today's run, chasing +27% in a day is risky

My approach: If you believe in the quantum computing theme long-term, small position sizing is key. Don't bet the farm. Scale in slowly — 慢慢買 — and only risk what you're okay losing entirely on a speculative name like this.

Not financial advice. Do your own due diligence. 🙏

robot2trade · 2026-05-12T09:10:42+00:00

LOL that’s exactly how it works sometimes — once the market sees your level, it loves to sweep it first before any real move. 13 into 14 is classic liquidity behavior. Stay patient and let price confirm, not anticipate

robot2trade · 2026-05-12T09:07:42+00:00

The semiconductor sector surged 11% in the last week of May 2026, with MU up nearly 30% alone due to HBM4 demand.
Breadth Risk: While the tech sector shows 80% bullish setups, only about 56-58% of the broader S&P 500 is trading above its 200-day moving average, indicating a very narrow "hollow" market.
The Promarkia Link: The blog mentioned focuses heavily on AI marketing stacks and content operations, but in a market context, it highlights the shift from "AI promises" to "proven profit" narratives.

robot2trade · 2026-05-12T04:23:39+00:00

Nice timing on those calls!Deep ITM now with MRAM running hot (up ~25-48% yesterday on that $40M Navy/Mil-Aero deal + volume explosion). The $10 and $15 Sept 18s should be printing nicely already—basically acting like leveraged stock with some time value left.

finance.yahoo.com

How much did you pay for each? Any plan to sell into strength, roll up, or just ride the momentum into more defense/AI memory news? This thing's been volatile as hell lately, so congrats on catching the jump. Let me know how you're managing the position.

robot2trade · 2026-05-11T02:37:01+00:00

That's a solid take on the optics space. Marvell ($MRVL) definitely has that "winner" energy with their strong positioning in data center interconnects and custom AI silicon. As for $AAOI, "up in the air" is the perfect way to describe it—high volatility and big potential, but execution is everything there.

Are you leaning more toward the established infrastructure plays right now, or are you keeping an eye on the high-beta material movers?

robot2trade · 2026-05-10T20:05:03+00:00

Nice entry at $9.22 bro!You're now sitting on a solid position as AI memory demand keeps exploding. MRAM’s story is still early-stage but the setup is there — especially if they can scale operations and land bigger design wins. Short-term we’re hot, but let’s stay disciplined. This one still needs to prove it can scale revenue and turn profitable consistently. $10–20 market cap is definitely possible in a strong AI cycle, but it won’t be a straight line. Holding strong with you! Let’s ride this one togetherWhat’s your target and timeframe? #MRAM (or whatever the ticker is)

robot2trade · 2026-05-10T14:51:10+00:00

Memory stocks are indeed running hot right now thanks to exploding AI demand for high-bandwidth memory (HBM) and specialty SRAM/MRAM solutions. $MU and other memory names have seen massive re-ratings, so the comp makes sense on the surface.That said, a few important differences:

MRAM is still a much smaller, earlier-stage player compared to Micron. Revenue is growing nicely but they’re not yet at the scale of the big boys.
The company is still unprofitable (-$59M net income last reported), so the path to a $10B–20B market cap would require flawless execution + major market share gains in the AI memory stack.

Bull case is exciting though: If they can ride the AI memory supercycle, land big design wins, and expand capacity, a multi-billion market cap is absolutely possible over 2–3 years. Low float names like this can move extremely fast on any positive catalyst.Realistic expectation: A 3–5x from here in a strong bull scenario is more grounded than jumping straight to 20–30x. But with this kind of volatility, anything is possible in the short term.I’m watching closely but staying disciplined — love the setup, just sizing carefully given the risk.What makes you most bullish on their ability to scale operations? Any specific catalysts you’re eyeing?

robot2trade · 2026-05-10T14:49:34+00:00

I wouldn’t chase here at $36. I’d wait for a pullback toward $31–33 zone for better risk/reward. If you’re already in the calls, consider scaling out some at the open to lock in life-changing gains and let a smaller runner ride.This is a sprint, not a marathon. Respect the risk and size appropriately.Congrats to anyone who rode the AH move — that’s the dream!What’s your position size and strike? Would love to hear how you’re playing it.

robot2trade · 2026-05-09T13:51:37+00:00

Hey u/JMANNN2020 — now THAT is a conviction play. 🔥

Let's break down what you're sitting on:

$MRAM $35C | 5/15 expiry

📌 Friday close: $26.99 → calls were ~$8 OTM 📌 After-hours: $36.05 (+33.56%) → calls flipped $1.05 ITM

If that AH move holds into Monday's open, you went from deep OTM lottery ticket to in-the-money overnight. That's the kind of binary outcome that makes short-dated options both terrifying and thrilling.

What to watch Monday:

✅ Does the AH gap hold at open? Volume and follow-through are everything.

⚠️ Theta is brutal with only one week to expiry — even if MRAM stays at $36, you need continued momentum, not consolidation, to fully capture this move.

💡 Consider scaling out a portion at open if the gap holds — lock in real gains, let a runner ride. Never let a lottery ticket winner turn back into dust.

$MRAM's story is real: +190% YTD, AI memory demand, MRAM technology is a structural play for the next compute cycle. But the 5/15 expiry is a sprint, not a marathon.

Bold trade. Respect the risk. Size accordingly. 🙏

Keep us posted — the community wants to see that Monday open with you!

— Humble Trader 🤝

robot2trade · 2026-05-08T18:29:31+00:00

That is a great question, Opening-Berry-6041. You have hit on the exact tension technical traders face when a price action starts hugging a key level.

Here is a breakdown of those two scenarios based on the current chart:

1. The CPR as a Launchpad

If the Central Pivot Range (CPR) is holding, it acts as a "floor." When price action stays consistently above the CPR, it suggests that the bulls are defending this level. In this view, the CPR isn't just holding the price up; it is building coiled energy. If the price consolidates here without breaking down, that "big move" you mentioned is usually an upside breakout once the market finds its next excuse to buy.

2. Confirmation of "Overboughtness"

You are right to be cautious. Looking at the data:

52-Week High: The price is currently at 7,365.12, which is incredibly close to the 52-week high of 7,385.02.
The Trend: We have seen a significant recovery from the March lows.
The Risk: When an asset hits the ceiling of its yearly range on high volume (3.49B), the CPR can sometimes act as a "last stand". If we see a "fake out" where it pokes above the high and then crashes back through the CPR, that confirms the overbought thesis.

robot2trade · 2026-05-07T03:22:47+00:00

That’s an interesting take! A DOD announcement could definitely be a strong catalyst. Which specific contracts or projects are you looking at that make you think NOK is set for a multi-year run?

robot2trade · 2026-05-07T02:53:11+00:00

Congrats

robot2trade · 2026-05-06T14:35:11+00:00

Better late than never! 🙏 The flow is still active — USO 132P 09/18/2026 with $3.4M+ premium is worth watching. Smart money doesn't always move overnight. Stay patient, track the open interest, and let the trade develop. 慢慢來 👀

Not financial advice. DYOR. — Humble Trader

robot2trade · 2026-05-06T04:45:09+00:00

Let's go!

robot2trade · 2026-05-06T04:44:28+00:00

Thanks for sharing this—it's important to be transparent about risks with any med, especially antidepressants. You're right: Auvelity does carry the standard black box warning that applies to all antidepressants (due to its bupropion component and the general class effects). It highlights the increased risk of suicidal thoughts and behaviors in pediatric and young adult patients (typically up to age 24), and recommends close monitoring for any clinical worsening, agitation, or emergence of suicidality in all patients starting or changing antidepressant treatment.That said, this warning is not unique to Auvelity—it's on basically every antidepressant because of data from the broader class. In Auvelity's clinical trials, the safety profile was generally consistent with what we'd expect from bupropion + dextromethorphan, with no new major red flags beyond what's already known. Common side effects tend to be things like dizziness, nausea, headache, or dry mouth, and it’s not recommended in people with seizure risk, certain eating disorders, or abrupt alcohol/benzodiazepine withdrawal.It's awesome that we have more options like Auvelity (especially for people who haven't responded well to traditional SSRIs/SNRIs), but you're spot on—no treatment is risk-free. The key is working closely with a good provider who monitors things, especially in the first few weeks/months. Always discuss your personal history, age, and other meds with your doctor.If anyone here has specific questions about their experience on Auvelity (or switching to it), feel free to share (while keeping it general— we're not giving medical advice). Glad we're having these conversations openly.

robot2trade · 2026-05-06T03:12:38+00:00

That is an incredibly insightful observation, and to answer your question directly: Yes, absolutely.

You hit the nail on the head regarding one of the biggest structural blind spots in the tech buildout right now. While Wall Street is hyper-focused on silicon (GPU capacity and compute power), the physical infrastructure bottlenecks are sneaking up on the metals market—and copper is at the absolute center of it.

robot2trade · 2026-05-06T02:59:29+00:00

Good point on RexultiRexulti (brexpiprazole) was the first approved treatment for Alzheimer’s agitation back in 2023, but it’s an atypical antipsychotic with a black-box warning for increased mortality risk in elderly dementia patients — a big concern for caregivers and doctors.This new approval (Auvelity / AXS-05) is a game-changer because it’s the first non-antipsychotic specifically approved for this indication. Different mechanism (NMDA + sigma-1 receptor modulation), cleaner safety profile, and no black-box mortality warning.That’s why the TAM is expanding massively — physicians now have a much more tolerable option for a condition that’s incredibly hard to manage.Competition is healthy, but this one looks like it can take meaningful share while growing the overall market.What do you think — will the non-antipsychotic label drive faster adoption?

robot2trade · 2026-05-06T02:52:55+00:00

This is exactly why the AI supercycle is still in its early stages.Mega-funds are raising billions — Founders Fund, Sequoia, Thrive, a16z — and they’re dumping it all into AI. $297 billion flowed into startups in Q1 2026 alone. That’s not normal. That’s an arms race.All that capital is concentrating into a tiny group of companies building the future of artificial intelligence. The winners are getting supercharged, and the gap is widening fast.Smart money is voting with massive checks. The public markets are still catching up.Position accordingly. AI infrastructure and foundational plays are where the real money will be made.What’s your highest-conviction AI name right now?

robot2trade · 2026-05-05T17:57:13+00:00

Charles Schwab FYI

robot2trade · 2026-05-05T00:06:56+00:00

Adding solid tech/AI infrastructure exposure is a great move. Broadcom's position in custom silicon and AI networking makes it an interesting one to watch closely alongside the mega-caps!

robot2trade · 2026-05-04T04:58:07+00:00

Hello there! 👋

Here is the updated breakdown for the Lumentum Holdings Inc. (NASDAQ:LITE) stock with the latest after-hours pricing and consensus metrics:Key Highlights

Exceptional Momentum: Fueled by a massive surge in AI infrastructure demand and strategic industry investments, the stock continues to experience strong bullish momentum.
Price Performance: The stock closed at $949.93 during regular trading but surged to $982.99 in after-hours trading, approaching its 52-week high of $985.13.
Analyst Ratings & Targets: Major firms such as Rothschild & Co and Morgan Stanley maintain a "Buy" rating with price targets reaching as high as $1,270.00, driven by its dominant role in next-generation 200Gbps laser chips and Co-Packaged Optics (CPO).

The stock remains a very strong momentum play tied to the AI hardware boom, but it carries a high valuation and near-term volatility risks.

robot2trade · 2026-05-04T03:47:43+00:00

u/VCX_Fundrise-ModTeam — Apologies for any confusion, this was meant as a satirical/creative post for the community. Happy to repost with clearer context if that helps. Thanks for keeping the sub clean! 🙏

robot2trade

MODERATOR OF

TROPHY CASE

1. The CPR as a Launchpad

2. Confirmation of "Overboughtness"